Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL ROSARIO-PRIETO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neuromuscular Medicine

NPI
1871738948
CMS profile
701785
Location
ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$50,324.73

185 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL ROSARIO-PRIETO

NPI 1871738948 · CMS profile ID 701785

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neuromuscular Medicine

ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871738948?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL ROSARIO-PRIETO, NPI 1871738948, CMS profile ID 701785. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871738948?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL ROSARIO-PRIETO, NPI 1871738948, CMS profile ID 701785. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871738948?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL ROSARIO-PRIETO, NPI 1871738948, CMS profile ID 701785, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1871738948?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

185 matching records · $50,324.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 185 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 185.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $29.0209/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228363747 CMS
PFIZER INC. $14.8409/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230322950 CMS
ABBVIE INC. $21.4609/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203926046 CMS
UCB, Inc. $26.9509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633761 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.0509/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223917286 CMS
Aucta Pharmaceuticals, Inc. $10.2409/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253338710 CMS
Teva Pharmaceuticals USA, Inc. $18.0709/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247347947 CMS
UCB, Inc. $8.9809/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633739 CMS
UCB, Inc. $8.9909/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633741 CMS
UCB, Inc. $17.5009/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633743 CMS
UCB, Inc. $17.5009/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633745 CMS
UCB, Inc. $20.8909/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633747 CMS
UCB, Inc. $33.0009/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633749 CMS
UCB, Inc. $33.0009/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633751 CMS
UCB, Inc. $38.8809/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633753 CMS
UCB, Inc. $2,500.0009/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224633755 CMS
UCB, Inc. $2,500.0009/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224633757 CMS
UCB, Inc. $4,800.0009/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224633759 CMS
Vanda Pharmaceuticals Inc. $24.5309/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232999288 CMS
UCB, Inc. $22.4309/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633737 CMS
Lundbeck LLC $31.9009/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251841281 CMS
UCB, Inc. $69.3108/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633735 CMS
Aucta Pharmaceuticals, Inc. $19.3608/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253622212 CMS
UCB, Inc. $140.6108/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633725 CMS
UCB, Inc. $140.6108/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633727 CMS
UCB, Inc. $140.6108/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633729 CMS
UCB, Inc. $280.6808/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633731 CMS
UCB, Inc. $280.6908/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633733 CMS
ARGENX US, INC. $30.0608/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240448084 CMS
UCB, Inc. $27.8508/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224633723 CMS
CSL Behring $21.6708/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232388587 CMS
GENZYME CORPORATION $38.2108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233509049 CMS
Genentech USA, Inc. $22.8608/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211549828 CMS
ARGENX US, INC. $8.8408/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240444319 CMS
Vanda Pharmaceuticals Inc. $28.2207/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232999286 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.1307/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223933201 CMS
Janssen Biotech, Inc. $26.1607/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175315588 CMS
Novartis Pharmaceuticals Corporation $25.5107/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200524264 CMS
ABBVIE INC. $16.6107/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203926041 CMS
UCB, Inc. $27.5007/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633719 CMS
UCB, Inc. $27.5007/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633721 CMS
Biogen, Inc. $22.8907/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208311719 CMS
PFIZER INC. $18.7207/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229883158 CMS
UCB, Inc. $630.0007/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1224633717 CMS
ABBVIE INC. $20.6407/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203926033 CMS
UCB, Inc. $35.0007/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633707 CMS
UCB, Inc. $44.0007/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633709 CMS
UCB, Inc. $106.8407/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633711 CMS
UCB, Inc. $112.5207/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224633713 CMS
UCB, Inc. $4,800.0007/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224633715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,143.60 124
PY2020 $704.52 37
PY2021 $1,199.90 22
PY2022 $11,681.18 59
PY2023 $25,029.36 170
PY2024 $76,000.77 236
PY2025 $50,324.73 185

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,407.58 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $69,798.20 12/10/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147080
Principal investigator 1 ARGENX US, INC. $15,000.00 12/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237147068
Principal investigator 1 ARGENX US, INC. $2,500.00 12/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237147072
Principal investigator 1 ARGENX US, INC. $6,160.00 11/12/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237147087
Principal investigator 1 ARGENX US, INC. $681.00 11/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147076
Principal investigator 1 ARGENX US, INC. $500.00 09/24/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147062
Principal investigator 1 ARGENX US, INC. $375.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147007
Principal investigator 1 ARGENX US, INC. $750.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147011
Principal investigator 1 ARGENX US, INC. $1,000.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147026
Principal investigator 1 ARGENX US, INC. $250.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147030
Principal investigator 1 ARGENX US, INC. $250.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147034
Principal investigator 1 ARGENX US, INC. $1,181.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147051
Principal investigator 1 ARGENX US, INC. $150.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147055
Principal investigator 1 ARGENX US, INC. $500.00 09/17/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147059
Principal investigator 1 ARGENX US, INC. $70.00 09/12/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147015
Principal investigator 1 ARGENX US, INC. $75.00 09/12/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147046
Principal investigator 1 ARGENX US, INC. $1,000.00 09/10/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237147038
Principal investigator 1 ARGENX US, INC. $2,800.00 09/10/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237147042
Principal investigator 1 ARGENX US, INC. $150.00 09/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147018
Principal investigator 1 ARGENX US, INC. $87,820.89 09/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147023
Principal investigator 1 ARGENX US, INC. $10,000.00 08/13/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237147083
Principal investigator 1 ARGENX US, INC. $52,326.45 05/09/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237146998
Principal investigator 1 ARGENX US, INC. $250.00 04/01/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147002
Principal investigator 1 ARGENX US, INC. $27,315.04 03/21/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147139
Principal investigator 1 ARGENX US, INC. $150.00 03/19/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147118
Principal investigator 1 ARGENX US, INC. $225.00 03/12/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147147
Principal investigator 1 ARGENX US, INC. $225.00 03/12/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147150
Principal investigator 1 ARGENX US, INC. $250.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147092
Principal investigator 1 ARGENX US, INC. $250.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147096
Principal investigator 1 ARGENX US, INC. $75.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147101
Principal investigator 1 ARGENX US, INC. $75.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147104
Principal investigator 1 ARGENX US, INC. $75.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147108
Principal investigator 1 ARGENX US, INC. $560.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147127
Principal investigator 1 ARGENX US, INC. $35.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147143
Principal investigator 1 ARGENX US, INC. $315.00 03/05/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147153
Principal investigator 1 ARGENX US, INC. $70.00 01/08/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147131
Principal investigator 1 ARGENX US, INC. $2,000.00 01/08/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147135
Principal investigator 1 ARGENX US, INC. $2,500.00 01/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147112
Principal investigator 1 ARGENX US, INC. $16,700.00 01/03/2025 Non-covered Recipient Entity
BAYCARE HEALTH SYSTEMS INC
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237147123